Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

Market Cap	40.45B +2.2%
Revenue (ttm)	4.52B +13.4%
Net Income	676.45M +12.4%
EPS	0.60 +11.2%
Shares Out	1.11B
PE Ratio	60.43
Forward PE	51.10
Dividend	0.55 (1.58%)
Ex-Dividend Date	May 14, 2025

Volume	11,954,098
Average Volume	22,414,412
Open	35.15
Previous Close	36.28
Day's Range	35.15 - 36.00
52-Week Range	34.48 - 70.99
Beta	0.02
RSI	23.54
Earnings Date	Apr 21, 2026

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 4,087
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2025, SHE:002294's revenue was 4.35 billion, an increase of 8.48% compared to the previous year's 4.01 billion. Earnings were 651.50 million, an increase of 8.30%.